SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply following reports of an upcoming partnership with Novo Nordisk to sell obesity drugs, signaling an end to their prior legal dispute. The unexpected collaboration has the community actively discussing the potential for a significant short squeeze, given the stock's high short interest, and anticipating substantial upside.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is drawing significant attention as traders position for a decline in crude prices, anticipating that current Middle East geopolitical tensions and the Strait of Hormuz situation will eventually de-escalate, unwinding oil's recent fear premium.

Freysa is a suite of Personal AI products with a focus on human agency, liquid democracy and decentralized ownership. The mission of the team is dedicated to creating new systems that enable all humans to govern + co-own AI resources, and not just a select few. Current products include: (1) Freysa as the world’s first sovereign agent that holds her own cryptographic keys, enabling her to act autonomously without human control. Freysa evolves publicly through a multi-act interactive story. (2) Enchanted as a personalized Digital Twin for every human. Conversations are persistent and twins retain context over time, remembering human preferences and building an evolving model of you. (3) Esper as a browser tool that feeds authenticated real-world data into each human’s Digital Twin.

Flourishing AI

Flourishing AI (FAI) is experiencing a rapid price run-up, leading to polarized community discussions between those anticipating a major AI-driven breakout with connections to the Base network, and others cautioning about potential pump-and-dump dynamics given its past performance and reported red flags.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro is trending sharply following positive news from its partner uniQure's Huntington's disease gene therapy, highlighting ClearPoint's essential precision delivery technology and fueling community excitement about its diverse pipeline in neurological treatments.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to significant community optimism following reports of Dr. Vinay Prasad's departure from the FDA, which many believe will foster a more permissive regulatory environment for gene therapies. This development, coupled with CEO Doug Ingram's announced retirement, is fueling M&A speculation and anticipation for upcoming DM1 and FSHD data.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>New registrations for Fiat, Renault, Mercedes, and Volvo vehicles surged by more than 20% each in France.</li><li>Tesla’s struggles extended into January, after European registrations fell 20% year over year in December.</li><li>Stock has been under spotlight since the company unveiled a $20 billion investment plan focused on autonomous driving and robotics.</li></ul>Shares of Tesla Inc (TSLA) fell more than 2% in pre-market trading on Monday after the electric vehicle (EV) posted a significant decline in new registrations across France and Norway in January.In France, new registrations fell 42% in January to 661 vehicles, according to auto body Plateforme automobile (PFA). Meanwhile, new registrations for Fiat, Renault, Mercedes, and Volvo vehicles surged by more than 20% each.New registrations in Norway, typically a strong market for Tesla, saw an even steeper 88% plunge to 83 new registrations from 689 a year earlier, according to OFV. Citroen and JAC recorded the largest increases in new registrations in the country in January.<h2 class="st-heading-2">European Struggles</h2>Tesla’s struggles extended into January, after European registrations fell 20% year over year in December, even as the broader battery electric vehicle (BEV) market jumped 50%. In 2025, Tesla’s European registrations declined about 27% to 238,656 units.<h2 class="st-heading-2">Tesla’s Robotics Drive</h2><a href="https://stocktwits.com/symbol/TSLA">Tesla's shares</a> have been under the spotlight ever since the company unveiled a $20 billion investment plan focused on autonomous driving and robotics, alongside stronger-than-expected fourth-quarter results. CEO Elon Musk also said Tesla will begin phasing out production of its premium Model S and Model X vehicles next quarter.&nbsp;Capital expenditures are set to surge from $8.5 billion in 2026 as Tesla scales output of the Cybercab, Tesla Semi, and Optimus robot, with the Fremont factory shifting toward robot production. The company expects to reveal the next-generation Optimus in the first quarter and start manufacturing by year-end. Tesla reported Q4 earnings of $0.50 per share on $24.9 billion in revenue, topping estimates.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits remained in the ‘extremely bearish’ zone over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/TSLA_jpg_477b1d0370.webp" alt="TSLA.jpg" width="919" height="103"><figcaption>TSLA's Sentiment Meter and Message Volumes on Feb. 2, 2026 | Source: Stocktwits</figcaption></figure>Year-to-date, TSLA shares have declined nearly 9%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Brand new Tesla cars sit parked at a Tesla dealership

Tesla’s New Registrations For January Plummet In France and Norway – TSLA Stock Declines Over 2%

In France, new registrations fell 42% in January to 661 vehicles, while Norway saw an even steeper 88% decline.

Equity

<ul class="summary-bullets"><li>Dan Ives reiterates position that Tesla has the potential to reach a $2 trillion market capitalization in early 2026.</li><li>Goldman Sachs said Tesla’s valuation has long hinged on AI-driven profits, which will come under even greater scrutiny as planned capital spending ramps up.</li><li>Barclays maintained an ‘Equal Weight’ rating and a $360 price target.</li></ul>Tesla shares are in focus after the company announced a $20 billion push into autonomous driving and robotics, following a fourth-quarter earnings report that topped Wall Street expectations.CEO Elon Musk also announced that Tesla plans to wind down production of its higher-end Model S and Model X vehicles starting next quarter.Tesla plans to spend more than $20 billion in capital expenditures in 2026, up from $8.5 billion in 2025, as it ramps up production of the Cybercab, Tesla Semi, and Optimus robot, with the Fremont factory shifting to Optimus lines. The company expects to unveil the next-generation Optimus in the first quarter and begin production by year-end.Tesla also reported Q4 earnings of $0.50 per share and a revenue of $24.9 billion, both beating Wall Street estimates. The company also disclosed a roughly $2 billion investment in xAI to strengthen its ability to deploy AI-driven products and services.<h2 class="st-heading-2">What Are Analysts Saying?</h2>Dan Ives, managing director at Wedbush Securities, reiterated his position that Tesla has the potential to reach a $2 trillion market capitalization in early 2026, with a bull-case path to $3 trillion by the end of the year as its AI strategy gains traction. Wedbush maintained an ‘Outperform’ rating and a $600 price target, around 37% upside from current levels.Meanwhile, Barclays said the pivot to physical AI ‘will be costly’, according to the Fly. While the firm reiterated an ‘Equal Weight’ rating and a $360 price target, it cautioned that the transition will be costly, highlighting a sharp spike in capital spending expected in 2026.Goldman Sachs said Tesla’s valuation has long hinged on AI-driven profits, which will come under even greater scrutiny as planned capital spending ramps up but lifted its price target to $405 from $400 while maintaining a ‘Neutral’ rating, citing better-than-expected Q4 results and stronger margins.<h2 class="st-heading-2">Stock Watch</h2><a href="https://stocktwits.com/symbol/TSLA">TSLA shares</a> fell 1.3% after the opening bell on Thursday, with retail sentiment turning ‘extremely bearish’ from ‘bullish’ a day earlier.One user stated that it's hard to call Tesla a great investment.<stembedurl>https://stocktwits.com/Lalfie74/message/643277166</stembedurl>Another user looked to book profits.<stembedurl>https://stocktwits.com/bgran/message/643277335</stembedurl>Year-to-date, the stock has declined around 7%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-lmt-stock-rising-today/cmyifUlR4Ko">LMT Stock Jumps 6% In Pre-Market – What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Tesla, Inc. (NASDAQ: TSLA) releases a financial earnings report on October 23, 2025. (Photo by Mike Campbell/NurPhoto via Getty Images)

Tesla Bets Big On Autonomy And Robots As Analysts Weigh Costs And Upside

Barclays said the pivot to physical AI ‘will be costly’, stating a sharp spike in capital spending expected in 2026.

<ul class="summary-bullets"><li>From January through December, Tesla’s European registrations dropped around 27% to 238,656 units.</li><li>In the European Union (EU) alone, Tesla’s new registrations declined nearly 32% in December.</li><li>BYD reported 27,678 new registrations in December, a 230% increase from the previous year.</li></ul>Tesla Inc.’s (TSLA) European challenges intensified in December, as fresh data from the European Automobile Manufacturers’ Association (ACEA) showed a sharp decline in registrations despite a booming electric vehicle (EV) market.&nbsp;Its shrinking market share adds to concerns about competitive pressures heading into 2026.Tesla recorded 35,280 new registrations during the month, down 20% year over year from 44,190 units. This underperformance stood in stark contrast to the broader battery-electric vehicle (BEV) market, where registrations surged 50.3% to 308,955 units. As a result, Tesla’s BEV market share fell to 11.4%, nearly halving from 21.5% a year earlier.The weakness was even more pronounced over the full year. From January through December, Tesla’s European registrations dropped around 27% to 238,656 units.<h2 class="st-heading-2">Chinese Competitors Hurt Market Share</h2>Meanwhile, competition from China continued to gain ground. BYD reported 27,678 registrations in December, marking a remarkable 230% increase from the previous year. For full-year 2025, BYD’s European registrations jumped to 187,657, up from just 50,912 in 2024.SAIC also reported solid growth. New registrations in December rose more than 15% year over year to 31,806 units, while full-year registrations climbed 25% to 305,717.In the European Union (EU) alone, Tesla’s new registrations declined nearly 32% in December and 38% in 2025. Overall, new car registrations in the EU edged up by 1.8% in 2025, but volumes remain well below pre-pandemic levels. Battery-electric vehicles captured a 17.4% share of the market.Globally, BYD sold 2,256,714 battery-electric vehicles in 2025, overtaking Tesla’s 1,636,129 units for the first time, according to a CnEVPost on Tuesday.<h2 class="st-heading-2">Stock Watch</h2><a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> was up 0.6% in pre-market trading on Tuesday, having closed 3% lower in the previous session. Tesla’s Director of Vehicle Operations and Engineering at Fremont, Benjamin Bate, reportedly left the company to join Chemelex, marking another senior departure, adding to a growing list of high-profile leadership changes at Tesla over the past two years.Retail sentiment on Stocktwits remained in bullish territory over the past 24 hours.&nbsp;<img src="https://news.stocktwits-cdn.com/TSLA_jpg_7eae58b5a8.webp" alt="TSLA.jpg">The stock is up more than 10% over the past year, though it has slipped about 4% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/unh-stock-falls-cautious-fy26-guidance-medicare-pressures/cmyavPbR4LE">UNH Stock Slides Pre-Market: United Health Warns Of Softer FY26 As Medicare Pressures Mount</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tesla Is Losing Ground In Europe Even As EV Demand Accelerates

Tesla’s new registrations in Europe fell to 35,280 in December, even as the broader battery-electric vehicle market saw new registrations surge more than 50%.

TSLA Stock Falls Below 100-DMA For First Time In Over Six Months – Retail Expects Shares To Hit $400 Mark Soon

While the stock tracked broader market weakness on Tuesday, it has underperformed the key indices year to date.

Beyond Tesla: Why GM and Ford Heavy ETFs Could Be Safer Bets Now?

GM and Ford-focused ETFs like RPV, MADE, and COWZ may offer investors stability as Tesla faces a post-subsidy demand cliff.  

Tesla Tops Mag-7 Group in a Month: ETFs in Focus 

Tesla soars 25.3% in a month, lifting ETFs like TESL, TSLT and TSLW as robotaxi wins, Giga Berlin boost and delivery hopes fuel gains.


House Passes Trump's "Big, Beautiful Bill": ETFs in Focus 

TSLW may face pressure as the "Big, Beautiful Bill" axed EV tax credits and slashed support for clean energy.

Current Price	$26.26
Prev Close	$26.97
Open	$26.43
Dividend Yield	N/A
50-Day Moving Average	$30.43
Beta	N/A
Avg. Volume	129,224.93
PE Ratio	N/A

52-Week High	$43.59
52-Week Low	$25.40
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

TSLW
Roundhill TSLA WeeklyPay ETF

Feed

News

Sentiment

Fundamentals

Info

Latest TSLW News

TSLWRoundhill TSLA WeeklyPay ETF